All Releases
 |
BioCryst to Speak at RBC Healthcare Conference
Feb 18, 2010
|
7.9 KB |
| |
BIRMINGHAM, Ala., Feb 18, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Stuart Grant, Senior Vice President and Chief Financial Officer of BioCryst, plans to speak as a participant on the Biodefense Panel at RBC Capital Market's Healthcare Conference in New York on Tuesday, March 2,...
|
|
BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update
Feb 4, 2010
|
17.5 KB |
| |
BIRMINGHAM, Ala., Feb 04, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the fourth quarter and year ended December 31, 2009.
"Over the past year, BioCryst has made great strides towards the goal of building an enduring and successful biopharmaceutical company," sai...
|
|
BioCryst To Present At 12th Annual BIO CEO & Investor Conference
Feb 1, 2010
|
7.8 KB |
| |
BIRMINGHAM, Ala., Feb 01, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, plans to provide a corporate summary and updates regarding its clinical programs for peramivir, forodesine and BCX4208 at the 12th Annual BIO...
|
|
BioCryst's Partner Shionogi Launches Peramivir In Japan Under The Name 'RAPIACTA'
Jan 26, 2010
|
11.2 KB |
| |
BIRMINGHAM, Ala., Jan 26, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. will launch RAPIACTA, intravenous (i.v.) peramivir anti-viral, to treat patients with influenza in Japan, on January 27, 2010. An English version of Shionogi's press release an...
|
|
BioCryst Pharmaceuticals to Announce Fourth Quarter 2009 Financial Results on February 4, 2010
Jan 21, 2010
|
8.8 KB |
| |
BIRMINGHAM, Ala., Jan 21, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its fourth quarter 2009 financial results will be released on Thursday, February 4, 2010. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and to provide a...
|
|
BioCryst's CTCL Pivotal Study Achieves Enrollment Target
Jan 15, 2010
|
13.4 KB |
| |
BIRMINGHAM, Ala., Jan 15, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has achieved its protocol-specified objective of enrolling 100 late-stage patients (Stage IIB to IVA) in its pivotal study for forodesine in the treatment of cutaneous T-cell lymphoma (CTCL). Top-line data i...
|
|
BioCryst's Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
Jan 13, 2010
|
10.9 KB |
| |
BIRMINGHAM, Ala., Jan 13, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has received marketing and manufacturing approval for intravenous (i.v.) peramivir to treat patients with influenza in Japan. Shionogi intends to commercially launch peramivir ...
|
|
BioCryst and moksha8 Announce Approval for the Importation & Use of peramivir in Mexico
Jan 12, 2010
|
11.5 KB |
| |
BIRMINGHAM, Ala., Jan 12, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that moksha8 has been granted approval from COFEPRIS (The Federal Commission for the Protection against Sanitary Risk) in Mexico for the importation and use of peramivir in patients with influenza associated with the...
|
|
BioCryst Announces Two Additional Peramivir Partnerships
Jan 11, 2010
|
10.9 KB |
| |
BIRMINGHAM, Ala., Jan 11, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed agreements with two additional partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities for territories outside of the U.S. BioCryst's ...
|
|
BioCryst's Partner Green Cross Files for Peramivir Regulatory Approval in South Korea
Jan 8, 2010
|
10.2 KB |
| |
BIRMINGHAM, Ala., Jan 08, 2010 /PRNewswire via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has been informed by its partner, Green Cross Corp., that Green Cross has filed a New Drug Application (NDA) in South Korea to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with ...
|
|
BioCryst to Present at J.P. Morgan Healthcare Conference
Jan 5, 2010
|
8.2 KB |
| |
BIRMINGHAM, Ala., Jan 5, 2010 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and other members of BioCryst's management team plan to provide a corporate summary and updates regarding its clinical programs for ...
|
|
BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
Dec 9, 2009
|
10.8 KB |
| |
BIRMINGHAM, Ala., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Charles A. Sanders, M.D. has been elected to the Company's Board of Directors. Dr. Sanders brings to BioCryst extensive experience as a corporate executive and director, physician and professor of medi...
|
|
BioCryst Announces Pricing of Public Offering of Common Stock
Nov 19, 2009
|
9.4 KB |
| |
BIRMINGHAM, Ala., Nov 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. All of the shares are being offered by BioCryst pursuant to an eff...
|
|
BioCryst Announces Proposed Public Offering of Common Stock
Nov 17, 2009
|
9.4 KB |
| |
BIRMINGHAM, Ala., Nov 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. BioCryst a...
|
|
BioCryst Receives First Peramivir Order From U.S. Government
Nov 5, 2009
|
11.2 KB |
| |
BIRMINGHAM, Ala., Nov 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced it has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5 million under a newly issued contract with the Department of Health...
|
|
BioCryst's Partner Shionogi Files for Peramivir Regulatory Approval in Japan
Nov 4, 2009
|
12.7 KB |
| |
BIRMINGHAM, Ala., Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its partner, Shionogi & Co., Ltd. has filed a New Drug Application (NDA) in Japan to seek regulatory approval for intravenous (i.v.) peramivir to treat patients with influenza. As a consequence of this...
|
|
BioCryst to Present at Oppenheimer Healthcare Conference
Oct 29, 2009
|
8.3 KB |
| |
BIRMINGHAM, Ala., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, and Stuart Grant, Chief Financial Officer of BioCryst, plan to provide a corporate summary at the Oppenheimer & Co., Inc. 20th Annua...
|
|
BioCryst Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Oct 29, 2009
|
19.5 KB |
| |
BIRMINGHAM, Ala., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
"BioCryst ...
|
|
Emergency Use Authorization Granted For BioCryst's Peramivir
Oct 23, 2009
|
11.5 KB |
| |
BIRMINGHAM, Ala., Oct 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Food and Drug Administration (FDA), in response to a request from the U.S. Centers for Disease Control and Prevention (CDC), has issued an emergency use authorization (EUA) for the investigatio...
|
|
BioCryst Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
Oct 22, 2009
|
8.7 KB |
| |
BIRMINGHAM, Ala., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its third quarter 2009 financial results will be released on Thursday, October 29, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and to p...
|
|
|
|
|
